PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 15974853-8 2005 FAS activity was blocked by the specific inhibitor cerulenin. Cerulenin 51-60 fatty acid synthase Homo sapiens 0-3 15974853-11 2005 In addition, the FAS inhibitor cerulenin was able to significantly reduce the proliferation of both NG and HGF cells. Cerulenin 31-40 fatty acid synthase Homo sapiens 17-20 15617971-3 2005 The effects of cerulenin, a specific, potent, noncompetitive inhibitor of fatty acid synthase (FAS), on growth of TCA-83 cells and normal gingival fibroblasts was determined by the MTT method, and the effect of cerulenin on apoptosis was determined by electrophoresis of cellular DNA. Cerulenin 15-24 fatty acid synthase Homo sapiens 74-93 15617971-3 2005 The effects of cerulenin, a specific, potent, noncompetitive inhibitor of fatty acid synthase (FAS), on growth of TCA-83 cells and normal gingival fibroblasts was determined by the MTT method, and the effect of cerulenin on apoptosis was determined by electrophoresis of cellular DNA. Cerulenin 15-24 fatty acid synthase Homo sapiens 95-98 15172643-7 2004 In addition, the specific inhibitor of FAS activity cerulenin was able to significantly reduce the proliferation of oral SCC cells. Cerulenin 52-61 fatty acid synthase Homo sapiens 39-42 15390078-4 2004 Remarkably, pharmacological FAS blockade using the mycotoxin cerulenin or the novel small compound C75 completely suppressed the state of Her-2/neu-induced malignant transformation by inhibiting the ability of NIH-3T3/Her-2 cells to grow under either anchorage-independent (i.e., to form colonies in soft agar) or low-serum monolayer conditions. Cerulenin 61-70 fatty acid synthase Homo sapiens 28-31 15254710-4 2004 Specifically, we examined the ability of the mycotoxin cerulenin, a potent and non-competitive inhibitor of FAS activity, to enhance the cytotoxic effects of vinorelbine (Navelbine), a derivative of vinca alkaloid that interferes with tubulin assembly and exhibits activity against metastatic breast cancer. Cerulenin 55-64 fatty acid synthase Homo sapiens 108-111 15235125-3 2004 Pharmacological FAS inhibitors cerulenin and C75 were found to suppress p185(HER2) oncoprotein expression and tyrosine-kinase activity in breast and ovarian HER2 overexpressors. Cerulenin 31-40 fatty acid synthase Homo sapiens 16-19 15047835-7 2004 Two specific FAS inhibitors, cerulenin and C75, prevent R activation of IE (Z) and early (BMRF1) lytic EBV proteins in Jijoye cells. Cerulenin 29-38 fatty acid synthase Homo sapiens 13-16 15138577-14 2004 Interestingly, a long-term exposure to pharmacological inhibitors of FAS activity cerulenin [(2S,3R) 2,3-epoxy-4-oxo-7E,10E-dodecadienamide] or C75 also resulted in a significant reduction of FAS accumulation. Cerulenin 82-91 fatty acid synthase Homo sapiens 69-72 15138577-14 2004 Interestingly, a long-term exposure to pharmacological inhibitors of FAS activity cerulenin [(2S,3R) 2,3-epoxy-4-oxo-7E,10E-dodecadienamide] or C75 also resulted in a significant reduction of FAS accumulation. Cerulenin 82-91 fatty acid synthase Homo sapiens 192-195 14999148-4 2004 Co-administration of docetaxel (Taxotere) and the mycotoxin cerulenin, a potent and non-competitive inhibitor of FAS activity, demonstrated strong synergism in HER -2/ neu -overexpressing and docetaxel-resistant SK-Br3 cells, modest synergism in moderately HER -2/ neu -expressing MCF-7 cells, and it showed additive effects in low HER -2/ neu -expressing and docetaxel-sensitive MDA-MB-231 cells. Cerulenin 60-69 fatty acid synthase Homo sapiens 113-116 14767544-10 2004 Pharmacological inhibition of FAS activity by the natural antibiotic cerulenin [(2S,3R)-2,3-epoxy-4-oxo-7E,10E-dodecadienamide] resulted in a dose-dependent cytotoxicity which positively paralleled the endogenous level of FAS. Cerulenin 69-78 fatty acid synthase Homo sapiens 30-33 14767544-10 2004 Pharmacological inhibition of FAS activity by the natural antibiotic cerulenin [(2S,3R)-2,3-epoxy-4-oxo-7E,10E-dodecadienamide] resulted in a dose-dependent cytotoxicity which positively paralleled the endogenous level of FAS. Cerulenin 69-78 fatty acid synthase Homo sapiens 222-225 14767544-16 2004 In SK-Br3 cells, cerulenin-induced inhibition of FAS activity resulted in down-regulation of p53, and up-regulation of cyclin-dependent kinase inhibitor (CDKi) p21WAF1/CIP1. Cerulenin 17-26 fatty acid synthase Homo sapiens 49-52 14767544-17 2004 Treatment with cerulenin or a novel small-molecule inhibitor of FAS C75 resulted in a dramatic accumulation of CDKi p27KIP1, which was accompanied by a noteworthy translocation of p27KIP1 from cytosol to cell nuclei. Cerulenin 15-24 fatty acid synthase Homo sapiens 64-67 14615481-6 2004 Cerulenin, a FAS inhibitor, causes a similar biphasic change in ATP levels, although levels do not exceed control. Cerulenin 0-9 fatty acid synthase Homo sapiens 13-16 12820377-9 2003 Finally, the FAS inhibitor cerulenin was investigated for its ability to suppress tumor cell growth. Cerulenin 27-36 fatty acid synthase Homo sapiens 13-16 12820377-12 2003 The antineoplastic properties of cerulenin documented here are consistent with prior studies showing its cytotoxic effects upon other types of cancer cells and illustrate the potential utility of FAS inhibition as a novel chemotherapeutic approach. Cerulenin 33-42 fatty acid synthase Homo sapiens 196-199 11866903-8 2000 CONCLUSION: The fatty acid synthase inhibitor, cerulenin, enables to induce cell apoptosis and to suppress the growth of human colonic cancer cells by inhibition of the synthesized fatty acids endogenously in the cancer cells. Cerulenin 47-56 fatty acid synthase Homo sapiens 16-35 11935210-1 2002 BACKGROUND AND PURPOSE: Human type I fatty acid synthase has been proposed as a chemotherapeutic target for the treatment of breast cancer based on the inactivation of human beta-ketoacyl synthase activity by cerulenin. Cerulenin 209-218 fatty acid synthase Homo sapiens 37-56 11245456-1 2001 Fatty acid synthetic metabolism is abnormally elevated in tumor cells, and pharmacological inhibitors of the anabolic enzyme fatty acid synthase (FAS), including the natural product cerulenin and the novel synthetic compound c75, are selective inhibitors of tumor cell growth. Cerulenin 182-191 fatty acid synthase Homo sapiens 125-144 11245456-1 2001 Fatty acid synthetic metabolism is abnormally elevated in tumor cells, and pharmacological inhibitors of the anabolic enzyme fatty acid synthase (FAS), including the natural product cerulenin and the novel synthetic compound c75, are selective inhibitors of tumor cell growth. Cerulenin 182-191 fatty acid synthase Homo sapiens 146-149 11876988-0 2000 [Proliferation inhibition and apoptosis induction of K562 cells by fatty acid synthase inhibitor--cerulenin]. Cerulenin 98-107 fatty acid synthase Homo sapiens 67-86 11876988-1 2000 OBJECTIVE: To investigate the effect of fatty acid synthase (FAS) inhibitor--cerulenin on K562 leukemia cells and its mechanism. Cerulenin 77-86 fatty acid synthase Homo sapiens 40-59 11876988-1 2000 OBJECTIVE: To investigate the effect of fatty acid synthase (FAS) inhibitor--cerulenin on K562 leukemia cells and its mechanism. Cerulenin 77-86 fatty acid synthase Homo sapiens 61-64 11876988-6 2000 CONCLUSION: Fatty acid synthase inhibitor--cerulenin inhibits proliferation of K562 cells but not of human fibroblasts. Cerulenin 43-52 fatty acid synthase Homo sapiens 12-31 12213216-6 2002 H-ras transformation sensitized MCF-10a cells to the FAS inhibitors cerulenin and C-75. Cerulenin 68-77 fatty acid synthase Homo sapiens 53-56 12181752-1 2002 Cerulenin, a fungal metabolite, is known to be a specific inhibitor of fatty acid synthase. Cerulenin 0-9 fatty acid synthase Homo sapiens 71-90 11866947-1 2000 OBJECTIVE: To determine the effects of fatty acid synthase inhibitor, cerulenin, on tumor growth of human colonic carcinoma (LoVo) in nude mice. Cerulenin 70-79 fatty acid synthase Homo sapiens 39-58 8631008-2 1996 Recent studies have shown that the FAS inhibitor, cerulenin, is selectively cytotoxic to cell lines derived from human malignancies, suggesting that those carcinoma cells are dependent upon endogenous fatty acid synthesis for growth. Cerulenin 50-59 fatty acid synthase Homo sapiens 35-38 9788612-1 1998 Pharmacological inhibitors of the anabolic enzyme, fatty acid synthase (FAS), including the natural product cerulenin and the novel compound c75, are selectively cytotoxic to cancer cells via induction of apoptosis, apparently related to the tumor cell phenotype of abnormally elevated fatty acid synthetic metabolism. Cerulenin 108-117 fatty acid synthase Homo sapiens 51-70 9788612-1 1998 Pharmacological inhibitors of the anabolic enzyme, fatty acid synthase (FAS), including the natural product cerulenin and the novel compound c75, are selectively cytotoxic to cancer cells via induction of apoptosis, apparently related to the tumor cell phenotype of abnormally elevated fatty acid synthetic metabolism. Cerulenin 108-117 fatty acid synthase Homo sapiens 72-75 9593836-13 1998 Finally, cell lines were treated with the FAS inhibitor cerulenin: almost all breast cancer lines were growth inhibited at significantly lower amounts of drug than normal cell lineages, suggesting that FAS plays a greater role in viability of tumor cells than normal cells. Cerulenin 56-65 fatty acid synthase Homo sapiens 42-45 9593836-13 1998 Finally, cell lines were treated with the FAS inhibitor cerulenin: almost all breast cancer lines were growth inhibited at significantly lower amounts of drug than normal cell lineages, suggesting that FAS plays a greater role in viability of tumor cells than normal cells. Cerulenin 56-65 fatty acid synthase Homo sapiens 202-205 8665507-2 1996 A substantial subset of human breast, ovarian, endometrial, colorectal, and prostatic cancers express elevated levels of fatty acid synthase, the major enzyme required for endogenous fatty acid biosynthesis, and carcinoma lines are growth inhibited by cerulenin, a noncompetitive inhibitor of fatty acid synthase. Cerulenin 252-261 fatty acid synthase Homo sapiens 121-140 8631008-7 1996 HL60 cells adapted to growth in serum- and fatty acid-free medium show a dose-dependent sensitivity to cerulenin, which is reversed by palmitate, the major product of FAS, indicating that cerulenin cytotoxicity is mediated through fatty acid starvation. Cerulenin 103-112 fatty acid synthase Homo sapiens 167-170 8631008-7 1996 HL60 cells adapted to growth in serum- and fatty acid-free medium show a dose-dependent sensitivity to cerulenin, which is reversed by palmitate, the major product of FAS, indicating that cerulenin cytotoxicity is mediated through fatty acid starvation. Cerulenin 188-197 fatty acid synthase Homo sapiens 167-170 31678479-5 2019 We demonstrate that pharmacologic manipulation of FASN or SCD1 enzymatic activity by non-toxic concentrations of cerulenin or CAY10566 decreases CHIKV genome replication. Cerulenin 113-122 fatty acid synthase Homo sapiens 50-54 34977875-6 2021 PCa cell growth was significantly inhibited through the decreased AKT signaling pathway by treatment with cerulenin, a chemical FASN inhibitor, which also downregulated PIP, PIP2, and PIP3 but not PI. Cerulenin 106-115 fatty acid synthase Homo sapiens 128-132 34483846-5 2021 SH-SY5Y cells and cortical neurons exposed to 10 h of OGD and 24 h of reoxygenation displayed prominent cell death when treated with the Acetyl-CoA carboxylase inhibitor TOFA or the fatty acid synthase inhibitor cerulenin. Cerulenin 212-221 fatty acid synthase Homo sapiens 182-201 8022791-6 1994 Supraphysiologic levels of palmitate, 14 microM in dimethyl sulfoxide, significantly reversed the growth inhibition caused by cerulenin at concentrations of up to 5 micrograms/ml, indicating that cerulenin-mediated growth inhibition was due to fatty acid synthase inhibition. Cerulenin 126-135 fatty acid synthase Homo sapiens 244-263 8022791-6 1994 Supraphysiologic levels of palmitate, 14 microM in dimethyl sulfoxide, significantly reversed the growth inhibition caused by cerulenin at concentrations of up to 5 micrograms/ml, indicating that cerulenin-mediated growth inhibition was due to fatty acid synthase inhibition. Cerulenin 196-205 fatty acid synthase Homo sapiens 244-263 35597782-9 2022 More importantly, knockdown of FASN with FASN shRNA or the inhibitors C75 and Cerulenin dramatically diminished LNM in vivo, suggesting that FASN plays an essential role in LNM of CC and the clinical application potential of FASN inhibitors. Cerulenin 78-87 fatty acid synthase Homo sapiens 31-35 35597782-9 2022 More importantly, knockdown of FASN with FASN shRNA or the inhibitors C75 and Cerulenin dramatically diminished LNM in vivo, suggesting that FASN plays an essential role in LNM of CC and the clinical application potential of FASN inhibitors. Cerulenin 78-87 fatty acid synthase Homo sapiens 141-145 35597782-9 2022 More importantly, knockdown of FASN with FASN shRNA or the inhibitors C75 and Cerulenin dramatically diminished LNM in vivo, suggesting that FASN plays an essential role in LNM of CC and the clinical application potential of FASN inhibitors. Cerulenin 78-87 fatty acid synthase Homo sapiens 225-229 25947066-6 2015 In most samples, the FASN inhibitor cerulenin markedly decreased FASN expression and cell viability and induced apoptosis. Cerulenin 36-45 fatty acid synthase Homo sapiens 21-25 29113229-4 2017 Cerulenin was used as a FASN inhibitor. Cerulenin 0-9 fatty acid synthase Homo sapiens 24-28 29113229-8 2017 Inhibition of FASN by cerulenin resulted in a significant decrease in expression of ErbB1, 2 and 4 (P<0.001), whereas there was no evident change in ErbB3. Cerulenin 22-31 fatty acid synthase Homo sapiens 14-18 28400509-7 2017 The inhibition of FASN by cerulenin, a small molecule antibiotic, blocked cellular proliferation of KRAS-associated lung cancer cells. Cerulenin 26-35 fatty acid synthase Homo sapiens 18-22 28260110-13 2017 The combined treatment of emodin and cerulenin, a commercial FASN inhibitor, had an additive effect on these activities. Cerulenin 37-46 fatty acid synthase Homo sapiens 61-65 27918556-5 2017 The effects of FASN inhibitors cerulenin and orlistat on the proliferation, apoptosis, and migration of human lymphatic endothelial cells (HDLEC) were evaluated with in vitro models. Cerulenin 31-40 fatty acid synthase Homo sapiens 15-19 27713913-6 2016 Pharmacological inhibition of FASN activity with the mycotoxin cerulenin or the small compound C75 reversed CCN1-induced acquisition of estrogen independence and resistance to hormone therapies such as tamoxifen and fulvestrant in anchorage-independent growth assays. Cerulenin 63-72 fatty acid synthase Homo sapiens 30-34 26936618-10 2016 Inhibition of FASN by cerulenin impaired glycolysis and migration in SK-BR-3 cells. Cerulenin 22-31 fatty acid synthase Homo sapiens 14-18 26808816-6 2016 When GSCs were treated with 20 muM cerulenin, a pharmacological inhibitor of FASN, their proliferation and migration were significantly suppressed and de novo lipogenesis decreased. Cerulenin 35-44 fatty acid synthase Homo sapiens 77-81 26109148-4 2016 METHODS: Cerulenin was used to suppress the FASN expression in human colorectal cancer cell lines (HT29 and LoVo). Cerulenin 9-18 fatty acid synthase Homo sapiens 44-48 26484401-3 2015 Inhibitors of fatty acid synthase, such as the cerulenin synthetic analog C75, decrease prostate cancer cell proliferation, increase apoptosis and decrease tumor growth in experimental models. Cerulenin 47-56 fatty acid synthase Homo sapiens 14-33 25825864-8 2015 Mammalian target of rapamycin (mTOR) was phosphorylated by hypoxia, whereas inhibition of FASN by cerulenin suppressed hypoxia-induced mTOR phosphorylation as well as UCB-hMSC proliferation and migration. Cerulenin 98-107 fatty acid synthase Homo sapiens 90-94 27765901-4 2016 We next investigated whether the inhibition of FASN by using a specific FASN inhibitor, cerulenin, can influence growth and EMT/metastatic potential of A549CisR and H157CisR cells. Cerulenin 88-97 fatty acid synthase Homo sapiens 47-51 27765901-4 2016 We next investigated whether the inhibition of FASN by using a specific FASN inhibitor, cerulenin, can influence growth and EMT/metastatic potential of A549CisR and H157CisR cells. Cerulenin 88-97 fatty acid synthase Homo sapiens 72-76 25947066-6 2015 In most samples, the FASN inhibitor cerulenin markedly decreased FASN expression and cell viability and induced apoptosis. Cerulenin 36-45 fatty acid synthase Homo sapiens 65-69 24866893-6 2014 Cerulenin, a FASN inhibitor, synergized with rapamycin to induce apoptosis and inhibit cell migration and tumorigenesis in ER/HER2-positive breast cancer cells. Cerulenin 0-9 fatty acid synthase Homo sapiens 13-17 24520215-7 2014 Cerulenin inhibited MCF-7-MEK5 cell migration and EMT, and reduced FASN expression and down-stream proteins L-FABP, VEGF, and VEGFR-2. Cerulenin 0-9 fatty acid synthase Homo sapiens 67-71 24520215-10 2014 Immunohistochemistry further showed that increased percentage of FASN-positive cells in the tumor tissue was associated with increased percentages of L-FABP- and VEGF-positive cells and the Cerulenin treatment could reverse the effect. Cerulenin 190-199 fatty acid synthase Homo sapiens 65-69 23108760-0 2013 Fatty acid synthase inhibitor cerulenin inhibits topoisomerase I catalytic activity and augments SN-38-induced apoptosis. Cerulenin 30-39 fatty acid synthase Homo sapiens 0-19 23816424-5 2013 FASN inhibitors (cerulenin, triclosan and orlistat) significantly inhibited FASN enzyme activity (P<0.05) in Y79 RB cells. Cerulenin 17-26 fatty acid synthase Homo sapiens 0-4 23816424-5 2013 FASN inhibitors (cerulenin, triclosan and orlistat) significantly inhibited FASN enzyme activity (P<0.05) in Y79 RB cells. Cerulenin 17-26 fatty acid synthase Homo sapiens 76-80 23754252-2 2013 Cerulenin, a natural inhibitor of fatty acid synthase, induced apoptosis in the human colon cancer cell lines HCT116 and RKO. Cerulenin 0-9 fatty acid synthase Homo sapiens 34-53 23108760-2 2013 One of the most widely used inhibitors of FASN, cerulenin, is a natural product of Cephalosporium caerulens. Cerulenin 48-57 fatty acid synthase Homo sapiens 42-46 20511185-5 2010 Second, we demonstrated that treatment with the FAS inhibitor, cerulenin (Cer), significantly decreased meningioma cell survival in vitro. Cerulenin 63-72 fatty acid synthase Homo sapiens 48-51 21643005-13 2011 Treatment of LM-MCF-7 cells with the FASN inhibitor cerulenin (10 mumol/L) reduced all the levels of p-ERK1/2, 5-LOX, and LTB4. Cerulenin 52-61 fatty acid synthase Homo sapiens 37-41 23181152-2 2010 The ocular cancer, retinoblastoma cells were treated with fatty acid synthase (FASN) enzyme inhibitors: cerulenin, triclosan and orlistat. Cerulenin 104-113 fatty acid synthase Homo sapiens 58-77 23181152-2 2010 The ocular cancer, retinoblastoma cells were treated with fatty acid synthase (FASN) enzyme inhibitors: cerulenin, triclosan and orlistat. Cerulenin 104-113 fatty acid synthase Homo sapiens 79-83 23181152-5 2010 The crystal structures of ketoacyl synthase (PDB ID:3HHD) (cerulenin) and thioesterase (PDB ID:2PX6) (orlistat) domains of human FASN were utilized for docking, while for the non-crystallised human FASN enoyl reductase domain (triclosan), homology model was built and used for docking. Cerulenin 59-68 fatty acid synthase Homo sapiens 129-133 23441619-3 2013 Differential gene expression in cultured retinoblastoma cells induced by cerulenin, a chemical inhibitor of FASN, was evaluated by cDNA microarray analysis. Cerulenin 73-82 fatty acid synthase Homo sapiens 108-112 23135268-6 2012 In addition, the proliferative effects induced by E2 and G-1 in these cells involved FASN as the inhibitor of its activity, named cerulenin, abolished the growth response to both ligands. Cerulenin 130-139 fatty acid synthase Homo sapiens 85-89 22771636-6 2012 We performed the cerulenin, an inhibitor of FASN, to inhibit FASN expression in U2-OS cells. Cerulenin 17-26 fatty acid synthase Homo sapiens 44-48 22771636-6 2012 We performed the cerulenin, an inhibitor of FASN, to inhibit FASN expression in U2-OS cells. Cerulenin 17-26 fatty acid synthase Homo sapiens 61-65 21389266-4 2011 In contrast to two agents, C75 and cerulenin, that are widely used as inhibitors of mammalian fatty acid synthase, platensimycin specifically inhibits fatty acid synthesis but not sterol synthesis in rat primary hepatocytes. Cerulenin 35-44 fatty acid synthase Homo sapiens 94-113 21170507-8 2011 The IC50 for the combined rosiglitazone and FASN blockers contrasts with the relatively higher IC50 for rosiglitazone (45 +- 2 muM), the TZD drug troglitazone (13 +- 2 muM), cerulenin (32 +- 1 muM), or C75 (26 +- 3 muM) when these drugs were used alone. Cerulenin 174-183 fatty acid synthase Homo sapiens 44-48 20973802-3 2010 However, the clinical use of FASN inhibitors, such as cerulenin, C75, and epigallocatechin 3-gallate (EGCG), is limited by anorexia and induced body weight loss or by its low in vivo potency and stability. Cerulenin 54-63 fatty acid synthase Homo sapiens 29-33 20511185-5 2010 Second, we demonstrated that treatment with the FAS inhibitor, cerulenin (Cer), significantly decreased meningioma cell survival in vitro. Cerulenin 74-77 fatty acid synthase Homo sapiens 48-51 20372807-4 2010 The FASN inhibitors cerulenin and orlistat reduced the growth of two LS cell lines (LiSa2, SW872), as did inhibition of ACC with soraphen A. Cerulenin 20-29 fatty acid synthase Homo sapiens 4-8 20373869-3 2010 Early small-molecule FASN inhibitors such as cerulenin, C75 and orlistat have been shown to induce apoptosis in several cancer cell lines and to induce tumor growth delay in several cancer xenograft models but their mechanism is still not well understood. Cerulenin 45-54 fatty acid synthase Homo sapiens 21-25 20126469-10 2010 Interestingly, we found that FAS was able to upregulate the expression of 5-LOX in a feedback manner by using cerulenin (an inhibitor of FAS). Cerulenin 110-119 fatty acid synthase Homo sapiens 29-32 20173757-7 2010 In function, flow cytometry analysis revealed that FAS contributed to the growth of hepatoma cells that was mediated by HBxDelta127, using cerulenin (a FAS inhibitor). Cerulenin 139-148 fatty acid synthase Homo sapiens 51-54 20173757-7 2010 In function, flow cytometry analysis revealed that FAS contributed to the growth of hepatoma cells that was mediated by HBxDelta127, using cerulenin (a FAS inhibitor). Cerulenin 139-148 fatty acid synthase Homo sapiens 152-155 20126469-10 2010 Interestingly, we found that FAS was able to upregulate the expression of 5-LOX in a feedback manner by using cerulenin (an inhibitor of FAS). Cerulenin 110-119 fatty acid synthase Homo sapiens 137-140 19932008-9 2010 In addition, each inhibitor for various lipid synthesis enzymes, such as TOFA (ACC inhibitor), cerulenin (FAS inhibitor) and trans-10, cis-12-CLA (SCD inhibitor), increased the MMP-1 expression significantly in a dose-dependent manner. Cerulenin 95-104 fatty acid synthase Homo sapiens 106-109 16969344-3 2006 Incubating glioma cells with the FAS inhibitor cerulenin decreased endogenous fatty acid synthesis by approximately 50%. Cerulenin 47-56 fatty acid synthase Homo sapiens 33-36 18723500-8 2008 The drop in PCho levels following FASN inhibition was confirmed in SKOV-3 ovarian cancer cells treated with Orlistat and in MCF-7 breast cancer cells treated with Orlistat as well as cerulenin. Cerulenin 183-192 fatty acid synthase Homo sapiens 34-38 18410446-1 2008 This study investigated the biological significance of the inhibition of fatty acid synthase (FAS) in multiple myeloma (MM) using the small molecule inhibitor Cerulenin. Cerulenin 159-168 fatty acid synthase Homo sapiens 73-92 18410446-1 2008 This study investigated the biological significance of the inhibition of fatty acid synthase (FAS) in multiple myeloma (MM) using the small molecule inhibitor Cerulenin. Cerulenin 159-168 fatty acid synthase Homo sapiens 94-97 18259941-6 2008 Importantly, CDDO-Im produced a dose-dependent apoptotic effect in the LiSa-2 cell line, and simultaneous treatment with CDDO-Im and the fatty acid synthase inhibitor Cerulenin produced a synergistic cytotoxic effect. Cerulenin 167-176 fatty acid synthase Homo sapiens 137-156 17786362-3 2007 Upon pharmacological inhibition of FASN activity using the natural antibiotic cerulenin [(2S,3R)-2,3-epoxy-4-oxo-7E,10E-dodecadienamide], we evaluated the role of FASN-catalyzed endogenous fatty acid biogenesis on the sensitivity of SK-Br3, MCF-7 and MDA-MB-231 breast cancer cell lines to the anti-metabolite 5-fluorouracil (5-FU). Cerulenin 78-87 fatty acid synthase Homo sapiens 35-39 17786362-3 2007 Upon pharmacological inhibition of FASN activity using the natural antibiotic cerulenin [(2S,3R)-2,3-epoxy-4-oxo-7E,10E-dodecadienamide], we evaluated the role of FASN-catalyzed endogenous fatty acid biogenesis on the sensitivity of SK-Br3, MCF-7 and MDA-MB-231 breast cancer cell lines to the anti-metabolite 5-fluorouracil (5-FU). Cerulenin 78-87 fatty acid synthase Homo sapiens 163-167 17786362-12 2007 Our current findings revealing a schedule-dependent synergistic interaction between 5-FU and cerulenin represents, to the best of our knowledge, the first evidence that FASN-catalyzed de novo FA biogenesis plays a key role in regulating breast cancer cell response to antimetabolite-based therapies. Cerulenin 93-102 fatty acid synthase Homo sapiens 169-173 18543396-11 2008 Cerulenin greatly inhibited metabolic activity/cell proliferation of U266 cells and induced apoptosis, suggesting that FAS is an effective target for pharmacological therapy in human multiple myeloma. Cerulenin 0-9 fatty acid synthase Homo sapiens 119-122 18410446-8 2008 Our results therefore indicate that inhibition of FAS by Cerulenin primarily triggered caspase-independent apoptosis and JNK-dependent cytotoxicity in MM cells. Cerulenin 57-66 fatty acid synthase Homo sapiens 50-53 17904792-0 2007 Fatty acid synthase inhibitors cerulenin and C75 retard growth and induce caspase-dependent apoptosis in human melanoma A-375 cells. Cerulenin 31-40 fatty acid synthase Homo sapiens 0-19 17904792-3 2007 The growth-inhibitory effects of FAS inhibitors cerulenin and C75 were then investigated on these cancer cell lines, particularly the human melanoma A-375. Cerulenin 48-57 fatty acid synthase Homo sapiens 33-36 17168665-2 2006 Since the pioneering observation that inhibition of FASN activity by the mycotoxin cerulenin preferentially kills cancer cells and retards the growth of tumors in xenografts models, numerous in vitro and in vivo studies have confirmed the potential of FASN as a target for antineoplastic intervention. Cerulenin 83-92 fatty acid synthase Homo sapiens 52-56 15878185-3 2005 Inhibition of FAS using cerulenin or synthetic FAS inhibitors such as C75 reduces food intake and induces profound reversible weight loss. Cerulenin 24-33 fatty acid synthase Homo sapiens 14-17 17343199-1 2006 OBJECTIVE: To determine whether fatty acid synthase (FAS) is expressed in human multiple myeloma( MM) cells and investigate the proliferation inhibition effect of fatty acid synthase inhibitor cerulenin on multiple myeloma cell line U266 and its mechanism. Cerulenin 193-202 fatty acid synthase Homo sapiens 163-182 15806173-6 2005 Treatment with LY294002 abolished AKT activity and potentiated apoptosis induced by FAS inhibitors cerulenin or C75 only in cells with constitutively active AKT, suggesting that constitutive activation of AKT protects against FAS inhibitor-induced cell death. Cerulenin 99-108 fatty acid synthase Homo sapiens 84-87 15806173-7 2005 Furthermore, inhibition of FAS activity by cerulenin or C75 resulted in downregulation of phospho-AKT, which preceded the induction of apoptosis. Cerulenin 43-52 fatty acid synthase Homo sapiens 27-30